The Impact of Stopping Zepbound: Weight Regain Study Reveals
TL;DR
A study published in the journal JAMA revealed that patients who discontinued treatment with Eli Lilly's weight-loss drug Zepbound experienced a 14% weight regain nearly a year later, while those who continued the treatment saw an additional 5.5% weight reduction. The drug, which targets the GLP-1 hormone to induce a feeling of fullness, is sold as Zepbound for weight loss and as Mounjaro for type 2 diabetes. The study highlights the need for longer-term therapy with GLP-1 drugs to maintain weight loss, as discontinuing such medications can lead to weight regain.
- Patients on Lilly's Zepbound regain weight after stopping treatment - study Reuters
- To keep pounds off, patients may need to continue taking weight loss drug, study suggests CNN
- How Much Weight Comes Back After Stopping a Weight-Loss Drug? The New York Times
- Weight Loss From Eli Lilly's Zepbound Reversed Slowly After Treatment Stopped Bloomberg
- What Happens When People Stop Taking the Weight Loss Drug Zepbound TIME
Want the full story? Read the original reporting
Read on Reuters